🇺🇸 FDA
Pipeline program

CE-326,597 100 mg QD

A7211005

Phase 2 small_molecule completed

Quick answer

CE-326,597 100 mg QD for Weight Management is a Phase 2 program (small_molecule) at Pfizer with 1 ClinicalTrials.gov record(s).

Program details

Company
Pfizer
Indication
Weight Management
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials